Keywords
kidney disease
prognosis
biomarker
How to Cite
Abstract
Neutrophil gelatinase- associated lipocalin (NGAL) is a protein molecule predominantly expressed in the distal nephron after the occurrence of renal injury. Unlike the serum creatinine and the glomerular filtration rate, which are the renal function markers, the increased levels of NGAL, both in serum and urine, are closely linked to the structural injury to the nephron. Clinical studies indicate that a few hours after the occurrence of acute renal injury, the serum and urinary levels of NGAL are already significantly elevated, while the serum creatinine levels and renal clearance only undergo significant changes between 24-48h after injury. Thus, the use of renal function markers, usually assessed in the clinical practice, they may have some limitations also hindering the implementation of early measures aimed at protecting the kidneys. This literature review aims at examining the biological aspects and the applications of NGAL measurement in some clinical conditions, including kidney failure, kidney diseases and renal ischemia.
References
1. MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 2005;11(15):5390-5. [DOI: 10.1158/1078-0432.CCR-04-2391].
2. Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood. 1994;83(3):799-807.
3. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 1996;38(3):414-20.
4. Hvidberg V, Jacobsen C, Strong RK, Cowland JB, Moestrup SK, Borregaard N. The endocytic receptor megalin binds the iron transporting neutrophil-gelatinase-associated lipocalin with high affinity and mediates its cellular uptake. FEBS Lett. 2005;579(3):773-7. [DOI: 10.1016/j.febslet.2004.12.031].
5. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al. Neutrophil Gelatinase–Associated Lipocalin (NGAL) as a Marker of Kidney Damage. Am J Kidney Dis. 2008;52(3):595-605. [DOI: 10.1053/j.ajkd.2008.01.020]
6. Yang J, Goetz D, Li JY, Wang W, Mori K, Setlik D, et al. An iron delivery pathway mediated by a lipocalin. Mol Cell. 2002;10(5):1045-56. [DOI: 10.1016/S1097-2765(02)00710-4].
7. Rubinstein T, Pitashny M, Putterman C. The novel role of neutrophil gelatinase-B associated lipocalin (NGAL)/Lipocalin-2 as a biomarker for lupus nephritis. Autoimmun Rev. 2008;7(3):229-34. [DOI: 10.1016/j.autrev.2007.11.013].
8. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: A multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011;57(17):1752-61. [DOI: 10.1016/j.jacc.2010.11.051].
9. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, 9. Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365(9466):1231–8. [DOI: 10.1016/S0140-6736(05)74811-x].
10. Fjaertoft G, Foucard T, Xu S, Venge P. Human neutrophil lipocalin (HNL) as a diagnostic tool in children with acute infections: A study of the kinetics. Acta Paediatr. 2005;94(6):661-6. [DOI:10.1080/08035250510031610].
11. Singer E, Markó L, Paragas N, Barasch J, Dragun D, Müller DN, et al. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf ). 2013;207(4):663-72. [DOI: 10.1111/apha.12054].
12. Glassock RJ. Prevention of microalbuminuria in type 2 diabetes: millimeters or milligrams. J Am Soc Nephrol. 2006;17(12):3276-8. [DOI: 10.1681/ASN.2006101131].
13. Devarajan, P. Review: Neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology (Carlton). 2010;15(4):419-28. [DOI: 10.1111/j.1440-1797.2010.01317.x].
14. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev. 2010;26(3):150-71. [DOI: 10.1002/dmrr.1068].
15. Flower DR. The lipocalin protein family: Structure and function. Biochem J. 1996;318(1):1-14. [DOI: 10.1042/bj3180001].
16. Goetz DH, Willie ST, Armen RS, Bratt T, Borregaard N, Strong RK. Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 2000;39(8):1935-41. [DOI:10.1021/bi992215v].
17. Tomonaga Y, Szucs T, Ambühl P, Nock S, Risch M, Risch L. Insights on urinary NGAL obtained in a primary care setting. Clin Chim Acta. 2012;413(7-8):733–9. [DOI: 10.1016/j.cca.2012.01.001].
18. Mori K, Lee HT, Rapoport D, Drexler IR, Foster K, Yang J, et al. Endocytic delivery of lipocalin-siderophoreiron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610–21. [DOI: 10.1172/JCI200523056].
19. Mahdavi-Mazdeh M, Abdollahi A, Nozary HB, Sobhani Z. Comparison of serum and urine neutrophil gelatinase-associated lipocalin (NGAL) with serum creatinine in prediction of kidney suitability for transplantation. Nephrourol Mon. 2013;5(1):679-82. [DOI: 10.5812/numonthly.5002].
20. Flo TH, Smith KD, Sato S, Rodriguez DJ, Holmes MA, Strong RK, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432(7019):917-21. [DOI:10.1038/nature03104].
21. Lassnigg A, Schmid ER, Hiesmayr M, Falk C, Druml W, Bauer P, et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med. 2008;36(4):1129–37. [DOI: 10.1097/CCM.0b013e318169181a].
22. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol. 2003;14(10):2534–43. [DOI:10.1097/01.ASN.0000088027.54400.C6].
23. Bennett M, Dent CL, Ma Q, Dastrala S, Grenier F, Workman R, et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol. 2008;3(3):665-673. [DOI: 10.2215/CJN.04010907].Haase M, Bellomo R, Devarajan P, Schlattmann P,
24. Haase-Fielitz A, NGAL Meta-analysis Investigator Group. Accuracy of Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Diagnosis and Prognosis in Acute Kidney Injury: A Systematic Review and Meta-analysis. Am J Kidney Dis. 2009;54(6):1012-24. [DOI: 10.1053/j.ajkd.2009.07.020].
25. Kim H, Hur M, Cruz DN, Moon HW, Yun YM. Plasma neutrophil gelatinase-associated lipocalin as a biomarker for acute kidney injury in critically ill patients with suspected sepsis. Clin Biochem. 2013;46(15):1414-8. [DOI: 10.1016/j.clinbiochem.2013.05.069].
26. Payen D, Lukaszewicz AC, Legrand M, Gayat E, Faivre V, Megarbane B, et al. A multicentre study of acute kidney injury in severe sepsis and septic shock: association with inflammatory phenotype and HLA genotype. PLoS One. 2012;7(6):e35838. [DOI: 10.1371/journal.pone.0035838].
27. Doi K, Urata M, Katagiri D, Inamori M, Murata S, Hisagi M, et al. Plasma neutrophil gelatinase-associated lipocalin in acute kidney injury superimposed on chronic kidney disease after cardiac surgery: a multicenter prospective study. Crit Care. 2013;17(6):R270. [DOI: 10.1186/cc13104].
28. Moon SJ, Park HB, Yoon SY, Lee SC. Urinary biomarkers for early detection of recovery in patients with acute kidney injury. J Korean Med Sci. 2013;28(8):1181-6. [DOI: 10.3346/jkms.2013.28.8.1181. Epub 2013 Jul 31].
29. Rostami Z, Nikpoor M, Einollahi B. Urinary neutrophil gelatinase associated lipocalin (NGAL) for early diagnosis of acute kidney injury in renal transplant recipients. Nephrourol Mon. 2013;5(2):745-52. [DOI: 10.5812/numonthly.9385].
30. Ibels LS, Gyory AZ, Caterson RJ, Pollock CA, Mahony JF, Waugh DA, et al. Primary IgA nephropathy: natural history and factors of importance in the progression of renal impairment. Kidney Int Suppl. 1997;61:S67–S70.
31. Ding H, He Y, Li K, Yang J, Li X, Lu R, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol. 2007;123(2):227-34. [DOI: 10.1016/j.clim.2007.01.010].
32. Peters HP, Waanders F, Meijer E, van den Brand J, Steenbergen EJ, van Goor H, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26(11):1-8. [DOI: 10.1093/ndt/gfr135].
33. Hinze CH, Suzuki M, Klein-Gitelman M, Passo MH, Olson J, Singer NG, et al. Neutrophil gelatinase–associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity. Arthritis Rheum. 2009;60(9):2772–81. [DOI: 10.1002/art.24751].
34. Yang CC, Hsieh SC, Li KJ, Wu CH, Lu MC, Tsai CY, et al. Urinary neutrophil gelatinase-associated lipocalin is a potential biomarker for renal damage in patients with systemic lupus erythematosus. J Biomed Biotechnol. 2012;2012:759313.[DOI: 10.1155/2012/759313].
35. Brunner HI, Bennett MR, Mina R, Suzuki M, Petri M, Kiani AN, et al. Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis. Arthritis Rheum. 2012;64(8):2687-97. [DOI: 10.1002/art.34426].
36. Yilmaz A, Sevketoglu E, Gedikbasi A, Karyagar S, Kiyak A, Mulazimoglu M, et al. Early prediction of urinary tract infection with urinary neutrophil gelatinase associated lipocalin. Pediatr Nephrol. 2009;24(12):2387–92. [DOI: 10.1007/s00467-009-1279-6].
37. Bagshaw SM, Bellomo R, Devarajan P, Johnson C, Karvellas CJ, Kutsiogiannis DJ, et. al. Review article: acute kidney injury in critical illness. Can J Anaesth. 2010;57(11):985–98. [DOI: 10.1007/s12630-010-9375-4].
38. Fanning N, Galvin S, Parke R, Gilroy J, Bellomo R, McGuinness S. A prospective study of the timing and accuracy of neutrophil gelatinase-associated lipocalin levels in predicting acute kidney injury in high-risk cardiac surgery patients. J Cardiothorac Vasc Anesth. 2016;30(1):76-81. [DOI: 10.1053/j.jvca.2015.07.034]. [Epub 2015 jul30].
39. Wyckoff T, Augoustides JG. Advances in acute kidney injury associated with cardiac surgery: the unfolding revolution in early detection. J Cardiothorac Vasc Anesth. 2012;26(2):340-5. [DOI: 10.1053/j.jvca.2012.01.001].
40. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology. 2006;105(3):485–91.
41. Parikh CR, Devarajan P, Zappitelli M, Sint K, Thiessen-Philbrook H, Li S, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol. 2011;22(9):1737-47. [DOI: 10.1681/ASN.2010111163].
42. Parving HH, Mauer M, Ritz E. In: Brenner & Rector’s The Kidney. 8ª ed. Boston (WB):Saunders; 2008.
43. Birn H, Christensen EI. Renal albumin absorption in physiology and pathology. Kidney Int. 2006;69(3):440–9. [DOI: 10.1038/sj.ki.5000141].
44. Brocco E, Fioretto P, Mauer M, Saller A, Carraro A, Frigato F, et al. Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int. 1997;63:S40–4.
45. Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR, et al. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med. 2010;27(10):1144-50. [DOI: 10.1111/j.1464-5491.2010.03083.x].
46. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Fazio MR, Nicocia G, et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res. 2009;32(2):91–8. [DOI: 10.1159/000209379].
47. Carvalho JAM, Tatsch E, Hausen BS, Bollick YS, Moretto MB, Duarte T, et al. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. Clin Biochem. 2016;49(3):232-6. [DOI: 10.1016/j.clinbiochem.2015.10.016]. [Epud 2015 Oct 27].
48. Grenier FC, Ali S, Syed H, Workman R, Martens F, Liao M, et al. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin Biochem. 2010;43(6):615–20.[DOI:10.1016/j.clinbiochem.2009.12.008].van de Vrie M, Deegens JK,
49. van der Vlag J, Hilbrands LB. Effect of long-term storage of urine samples on measurement of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Am J Kidney Dis. 2014;63(4):573-6. [DOI:10.1053/j.ajkd.2013.10.010].
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2016 Instituto Adolfo Lutz Journal